Document is current
Any future updates will be listed below
-
Authors
Imaide, Satomi https://orcid.org/0000-0003-4372-4693
Riching, Kristin M. https://orcid.org/0000-0003-4646-1067
Makukhin, Nikolai
Vetma, Vesna
Whitworth, Claire https://orcid.org/0000-0003-3174-7652
Hughes, Scott J.
Trainor, Nicole
Mahan, Sarah D.
Murphy, Nancy
Cowan, Angus D. https://orcid.org/0000-0002-9702-7319
Chan, Kwok-Ho https://orcid.org/0000-0002-6693-2682
Craigon, Conner
Testa, Andrea
Maniaci, Chiara https://orcid.org/0000-0001-7887-7388
Urh, Marjeta https://orcid.org/0000-0003-2148-0341
Daniels, Danette L. https://orcid.org/0000-0002-7659-3020
Ciulli, Alessio https://orcid.org/0000-0002-8654-1670
- License Information
-
More Information
Article History
Received: 26 November 2020
Accepted: 10 August 2021
First Online: 21 October 2021
Competing interests
: The authors declare the following competing financial interest(s): the Ciulli laboratory receives or has received sponsored research support from Almirall, Amphista therapeutics, Boehringer Ingelheim, Eisai, Nurix therapeutics and Ono Pharmaceuticals. A.C. is a scientific founder, shareholder and consultant of Amphista therapeutics, a company that is developing targeted protein degradation therapeutic platforms. Promega Corporation is the commercial owner by assignment of patents of the HaloTag, NanoLuc, NanoBRET target engagement and HiBiT technologies and their applications, and K.M.R., S.D.M., N.M., M.U. and D.L.D. are employees of Promega Corporation. S.I. is an employee of Ono Pharmaceuticals. S.J.H. and A.T. are employees of Amphista therapeutics. K.-H.C. is an employee of GlaxoSmithKline.
